Trellis Bioscience

Trellis Bioscience is a private company based in Redwood City, California. The company has 11 employees and generates approximately $50 million in annual revenue. Trellis Bioscience is a therapeutic antibody company focused on developing innovative treatments. Their core technology, CellSpotTM, allows them to isolate high-quality antibodies directly from human blood cells. This platform has attracted significant attention from global pharmaceutical companies, including MedImmune/AstraZeneca, which licensed a CellSpot-derived antibody targeting Respiratory Syncytial Virus (RSV) in a deal valued at $338 million. Trellis Bioscience's unique CellSpotTM platform sets them apart in the industry. This technology has been validated through peer-reviewed publications and has proven successful in generating pre-clinical antibodies with potential for treating significant diseases like RSV. For more information about Trellis Bioscience and their groundbreaking work, visit their website at trellisbio.com.